Search Results - "Michaelson, D. M."

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma by Patil, S., Figlin, R.A., Hutson, T.E., Michaelson, M.D., Négrier, S., Kim, S.T., Huang, X., Motzer, R.J.

“…Analysis of prognostic factors for progression-free survival (PFS) and overall survival (OS) was performed using final data from a randomized phase III trial…”
Get full text

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial by Escudier, B, Michaelson, M D, Motzer, R J, Hutson, T E, Clark, J I, Lim, H Y, Porfiri, E, Zalewski, P, Kannourakis, G, Staehler, M, Tarazi, J, Rosbrook, B, Cisar, L, Hariharan, S, Kim, S, Rini, B I

“…Background: In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously…”
Get full text

Opposing actions of environmental enrichment and Alzheimer’s disease on the expression of hippocampal microRNAs in mouse models by Barak, B, Shvarts-Serebro, I, Modai, S, Gilam, A, Okun, E, Michaelson, D M, Mattson, M P, Shomron, N, Ashery, U

“…Alzheimer’s disease (AD) is the most common form of dementia in the elderly. Although there are no drugs that modify the disease process, exposure to an…”
Get full text

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma by Cella, D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Michaelson, M D, Motzer, R J

“…Background: In a randomized phase III trial of sunitinib vs interferon-alfa (IFN- α ) in metastatic renal cell carcinoma (mRCC), better baseline quality of…”
Get full text

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis by Cella, D, Michaelson, M D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Kim, S T, Li, J Z, Motzer, R J

“…Background: In a randomised phase III trial, sunitinib significantly improved efficacy over interferon- α (IFN- α ) as first-line therapy for metastatic renal…”
Get full text

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α by Patil, S, Figlin, R A, Hutson, T E, Michaelson, M D, Negrier, S, Kim, S T, Huang, X, Motzer, R J

“…Background: In a randomised phase III trial of treatment-naive patients with metastatic renal cell carcinoma, sunitinib showed significant improvement in…”
Get full text

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study by Michaelson, M D, Zhu, A X, Ryan, D P, McDermott, D F, Shapiro, G I, Tye, L, Chen, I, Stephenson, P, Patyna, S, Ruiz-Garcia, A, Schwarzberg, A B

“…Background: This phase I, dose-finding study determined the maximum tolerated dose (MTD), safety, and pharmacokinetics of sunitinib plus gemcitabine in…”
Get full text

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma by Négrier, S, Bushmakin, A.G, Cappelleri, J.C, Korytowsky, B, Sandin, R, Charbonneau, C, Michaelson, M.D, Figlin, R.A, Motzer, R.J

“…Abstract Background To determine suitability of progression-free survival (PFS) as a surrogate end-point for overall survival (OS), we evaluated the…”
Get full text

APOE genotype is a major predictor of long-term progression of disability in MS by CHAPMAN, J, VINOKUROV, S, ACHIRON, A, KARUSSIS, D. M, MITOSEK-SZEWCZYK, K, BIRNBAUM, M, MICHAELSON, D. M, KORCZYN, A. D

“…The authors recently reported that the APOE epsilon4 allele is associated with significantly greater progression of disability in a 2-year follow-up of…”
Get full text

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer by Michaelson, M.D., Bellmunt, J., Hudes, G.R., Goel, S., Lee, R.J., Kantoff, P.W., Stein, C.A., Lardelli, P., Pardos, I., Kahatt, C., Nieto, A., Cullell-Young, M., Lewis, N.L., Smith, M.R.

“…This multicenter phase II trial evaluated the efficacy and safety of trabectedin in metastatic castration-resistant prostate cancer (CRPC). Two schedules were…”
Get full text

Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury by Chen, Y, Lomnitski, L, Michaelson, D.M, Shohami, E

“…Previous studies suggest that traumatic brain injury is associated with increased risk factor for developing Alzheimer's disease. Furthermore, the extent of…”
Get full text

The Interplay Between Apolipoprotein E4 and the Autophagic–Endocytic–Lysosomal Axis by Schmukler, E., Michaelson, D. M., Pinkas-Kramarski, R.

“…Since its discovery as a genetic risk factor for Alzheimer’s disease, the APOE4 allele has been linked to the majority of the pathological findings associated…”
Get full text

Antibodies to brain antigens following stroke by BORNSTEIN, N. M, ARONOVICH, B, KORCZYN, A. D, SHAVIT, S, MICHAELSON, D. M, CHAPMAN, J

“…Cerebral necrosis following stroke exposes brain antigens to the immune system, potentially initiating an antibody response. The authors measured levels of…”
Get full text

The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma by McGregor, B A, Sonpavde, G P, Kwak, L, Regan, M M, Gao, X, Hvidsten, H, Mantia, C M, Wei, X X, Berchuck, J E, Berg, S A, Ravi, P K, Michaelson, M D, Choueiri, T K, Bellmunt, J

“…The antibody-drug conjugates sacituzumab govitecan (SG) and enfortumab vedotin (EV) are standard monotherapies for metastatic urothelial carcinoma (mUC). Given…”
Get more information

Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: The allele E3 is neuroprotective whereas E4 increases fatalities by Sabo, T, Lomnitski, L, Nyska, A, Beni, S, Maronpot, R.R, Shohami, E, Roses, A.D, Michaelson, D.M

“…Apolipoprotein E, the major brain lipid-binding protein, is expressed in humans as three common isoforms (E2, E3 and E4). Previous studies revealed that the…”
Get full text

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma by Lee, Chung-Han, Motzer, Robert J., Glen, Hilary, Michaelson, M. D., Larkin, James, Minoshima, Yukinori, Kanekiyo, Michio, Ikezawa, Hiroki, Sachdev, Pallavi, Dutcus, Corina E., Funahashi, Yasuhiro, Voss, Martin H.

“…Background No biomarkers have been established to predict treatment efficacy in renal cell carcinoma (RCC). In an exploratory retrospective analysis of a Phase…”
Get full text

Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder by MICHAELSON, M. D, SHIPLEY, W. U, HENEY, N. M, ZIETMAN, A. L, KAUFMAN, D. S

“…Invasive transitional cell carcinoma (TCC) of the urinary bladder is traditionally treated with radical cystectomy. This approach results in great morbidity…”
Get full text

M1 Muscarinic Agonist Treatment Reverses Cognitive and Cholinergic Impairments of Apolipoprotein E‐Deficient Mice by Fisher, A., Brandeis, R., Chapman, S., Pittel, Z., Michaelson, D. M.

“…: Recent studies suggest that apolipoprotein E (apoE) plays a specific role in brain cholinergic function and that the E4 allele of apoE (apoE4), a major risk…”
Get full text

Site‐Specific Dephosphorylation of Tau of Apolipoprotein E‐Deficient and Control Mice by M1 Muscarinic Agonist Treatment by Genis, I., Fisher, A., Michaelson, D. M.

“…: Apolipoprotein E (apoE)‐deficient mice have memory deficits that are associated with synaptic loss of basal forebrain cholinergic projections and with…”
Get full text

Lack of apolipoprotein-E exacerbates experimental allergic encephalomyelitis by Karussis, D, Michaelson, D M, Grigoriadis, N, Korezyn, A D, Mizrachi-Koll, R, Chapman, S, Abramsky, O, Chapman, J

“…Experimental autoimmune encephalomyelitis (EAE) was found to have a chronic and significantly worse course in apolipoprotein-E (apoE) deficient female mice…”
Get full text